Headache News and Research

Latest Headache News and Research

FDA grants priority review of Cinryze C1 inhibitor as treatment for acute attacks of hereditary angioedema

ViroPharma Incorporated has announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of Hereditary Angioedema (HAE).

5 Feb 2009

Discovery introduces a lot of new questions about nervous system

A delay in traffic may cause a headache, but a delay in the nervous system can cause much more.

3 Feb 2009

Economic burden of migraine in the U.S.

A new study published in Value in Health reviews the economic burden of migraine in the U.S. and recent clinical findings of the health risks of this neurological condition.

2 Feb 2009

Healthcare will be a headache for Obama

Among industrialised nations, the US spends well over twice the per capita average on health care and soaring health costs are expected to reach 20 per cent of Gross Domestic Product by 2015.

23 Jan 2009

Migraines linked to mental disorders

Migraine headaches can precede the onset of mental disorders, according to a growing body of knowledge that includes a new study in the January-February 2009 issue of General Hospital Psychiatry.

21 Jan 2009

FDA approves RiaSTAP for bleeding in patients with congenital fibrinogen deficiency

The U.S. Food and Drug Administration has licensed RiaSTAP, an orphan drug for the treatment of bleeding in patients with a rare genetic defect known as congenital fibrinogen deficiency. Without treatment, these patients are at risk of potentially life-threatening bleeding.

18 Jan 2009

Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients

Baxter International Inc. and Halozyme Therapeutics, Inc. gas announced the start of a Phase 3 clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze Technology) for the treatment of primary immunodeficiency (PID).

From Baxter International Inc. 5 Jan 2009

Dengue fever outbreak now in Townsville

While health authorities continue to battle to contain an outbreak of Dengue fever in Cairns in north Queensland, further down the coast an outbreak has now been reported in Townsville.

5 Jan 2009

Schering-Plough announces European submission of fertility medicine Corifollitropin Alfa

Schering-Plough Corp. has announced that the European Medicines Agency (EMEA) has validated (accepted for review) its Marketing Authorization Application (MAA) for corifollitropin alfa, the company's experimental, sustained follicle stimulant (SFS).

1 Jan 2009

Brits battling to cope with 'killer' Australian flu strain

As doctors and hospitals in the UK struggle to deal with a flu epidemic, Brits are being warned that the current outbreak is expected to intensify in the new year as the potentially fatal Australian strain of influenza spreads across the country.

30 Dec 2008

Avoid headbanging injury by switching to Celine Dion?

Australian researchers have issued a warning about the danger of "head-banging" which is usually associated with heavy-metal music.

22 Dec 2008

Dengue fever outbreak spreading across Cairns

An outbreak of dengue fever in Cairns, in far north Queensland, continues to cause alarm as the number now affected has reportedly reached 50 and appears to be rising.

22 Dec 2008

AstraZeneca submits sNDA for NEXIUM (esomeprazole magnesium)

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for NEXIUM(R) (esomeprazole magnesium) to seek approval for the short-term (up to 6 weeks) treatment of gastroesophageal reflux disease (GERD) in pediatric patients ages 0 to 1 year old.

21 Dec 2008

Allergic rhinitis not associated with snoring or daytime sleepiness

Allergic rhinitis does not appear to be associated with snoring or daytime sleepiness, but individuals with obstructed nasal passages are likely to experience both regardless of whether they have allergies, according to a report in the December issue of Archives of Otolaryngology-Head & Neck Surgery.

15 Dec 2008

Cymbalta (duloxetine HCl) shown to delay new episodes of depression

New data suggest that Cymbalta (duloxetine HCl) 60 mg to 120 mg once daily delayed the onset of a new episode of depression in patients who had previously responded to the medication and who had recurrent depressive disorder, defined in the study as those patients who experienced at least three depressive episodes in the previous five years, compared with placebo (p < .001).

14 Dec 2008

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

New data released demonstrates that the addition of Zometa (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease.

14 Dec 2008

Australians warned of rabies outbreak in Bali

The warning comes from the head of the Northern Territory's Centre for Disease Control, Dr. Peter Markey, who says anyone bitten or scratched on the island by an animal should seek medical advice; the warning also applies to people who have been to Bali recently.

14 Dec 2008

AstraZeneca responds to FDA advisory committees' recommendation on SYMBICORT

On December 11, 2008, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) - including the Drug Safety & Risk Management Advisory Committee, the Pediatric Advisory Committee, and the Pulmonary-Allergy Drugs Advisory Committee - completed a review of the benefits and risks of asthma medications containing long-acting beta-agonists (LABAs).

12 Dec 2008

Merck Serono's Kuvan receives European marketing authorization

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the European Commission has granted marketing authorization for Kuvan(R) for the treatment of hyperphenylalaninemia (HPA) in phenylketonuria (PKU) or BH4 deficient patients.

10 Dec 2008

Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) is continuing with its review of the regulatory application for use of Byetta (exenatide) injection as stand-alone therapy (monotherapy) in people with type 2 diabetes who are not achieving acceptable blood sugar control.

8 Dec 2008

Headache News and Research

Latest Headache News and Research

FDA grants priority review of Cinryze C1 inhibitor as treatment for acute attacks of hereditary angioedema

Discovery introduces a lot of new questions about nervous system

Economic burden of migraine in the U.S.

Healthcare will be a headache for Obama

Migraines linked to mental disorders

FDA approves RiaSTAP for bleeding in patients with congenital fibrinogen deficiency

Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients

Dengue fever outbreak now in Townsville

Schering-Plough announces European submission of fertility medicine Corifollitropin Alfa

Brits battling to cope with 'killer' Australian flu strain

Avoid headbanging injury by switching to Celine Dion?

Dengue fever outbreak spreading across Cairns

AstraZeneca submits sNDA for NEXIUM (esomeprazole magnesium)

Allergic rhinitis not associated with snoring or daytime sleepiness

Cymbalta (duloxetine HCl) shown to delay new episodes of depression

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

Australians warned of rabies outbreak in Bali

AstraZeneca responds to FDA advisory committees' recommendation on SYMBICORT

Merck Serono's Kuvan receives European marketing authorization

Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Headache News and Research

Latest Headache News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in